A novel natural killer cell line (KHYG-1) from a patient with aggresive natural killer cell leukemia carrying a p53 point mutation

Leukemia

Volumn 14, Issue 5, 2000, Pages 922-930

  Yagita, M ^a   Huang, C L ^a   Umehara, H ^b   Matsuo, Y ^c   Tabata, R ^a   Miyake, M ^a   Konaka, Y ^a   Takatsuki, K ^a  

^a Kitano Hospital   (Japan)

^b OSAKA DENTAL UNIVERSITY   (Japan)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Cell line; NK cell leukemia; P53; Point mutation

Indexed keywords

CD1 ANTIGEN; CD16 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CELL CULTURE; CELL GRANULE; CELL LINE; CELL NUCLEUS; CELL STRUCTURE; CHROMATIN; CYTOPLASM; EPSTEIN BARR VIRUS; EXON; FEMALE; GERM LINE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NUCLEOLUS; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; VIRUS GENOME;

EID: 0034010658     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401769     Document Type: Article

References (52)

1. Loughran TP. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
2. Loughran TP, Starkebaum G. Large granular lymphocyte leukemia. Medicine 1987; 66: 397-405.
3. Semenzato C, Pandolfi F, Chisesi T, DeRossi G, Pizzolo G, Zambello R, Trentin L, Agostini C, Dini E. Vespignani M, Cafaro A, Pasqualetti D, Giubellono C, Migone N, Foa R. The lympho-proliferative disease of granular lymphocytes. Cancer 1987; 60: 2971-2978.
4. Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult and establishment of an NK cell line. Blood 1986; 67: 925-930.
5. +, Leu-7 surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2. Blood 1986; 68: 1065-1073.
6. Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, Bongiovanni KF, Waldmann TA. Leukemia of non-T lineage natural killer cells. Blood 1988; 72: 1701-1707.
7. Kawa-Ha K, Ishihara S, Ninomiya T, Yagi K, Hara J, Murayama F, Tawa A, Hirai K. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989; 84: 51-55.
8. Imamura N, Kusunoki Y, Kawa-Ha K, Yunuma K, Hara J, Oda K, Abe K, Dohy H, Inada T, Kajihara H, Kuramoto A. Aggressive natural killer cell leukemia/lymphoma: report of four cases and review of the literature. Br J Haematol 1990; 75: 49-59.
9. Hart DNJ, Baker BW, Ingkis MJ, Nimmo JC, Starling GC, Deacon E, Rowe M, Beard MEJ. Epstein-Barr viral DNA in acute large granular lymphocytes (natural killer) leukemic cells. Blood 1992; 79: 2116-2123.
10. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207-1210.
11. + aggressive variant of large granular lymphocyte leukemia. Blood 1994; 84: 2315-2321.
12. Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JP. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996; 87: 1474-1483.
13. Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994; 180: 569-576.
14. Ichinohasama R, Endoh K, Ishizawa K, Okuda M, Kameoka J, Meguro K, Myers J, Kadin ME, Mori S, Sawai T. Thymic lymphoblastic lymphoma of committed natural killer cell precursor origin. Cancer 1996; 77: 2592-2603.
15. Suzuki R, Yamamoto K, Seto M, Kagami Y, Ogura M, Yatabe Y, Suchi T, Kodera Y, Morishima Y, Takahashi T, Saito H, Ueda R, Nakamura S. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 1997; 90: 2417-2428.
16. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543-546.
17. Preudhomme C, Fenaux P. The clinical significance of mutations of the p53 tumor suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502-511.
18. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Wattel E, Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9: 370-381.
19. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 1997; 337: 529-534.
20. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen D, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H. Koeffler HP. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163-3169.
21. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477-480.
22. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128-135.
23. Homma T, Suzuki K, Kudo Y, Inagawa M, Mizuno S, Yamaguchi K, Tagawa M. Preparation and characterization of monoclonal antibodies against human myeloperoxidase. Arch Biochem Biophys 1989; 273: 189-196.
24. Almasri NM, Iturraspe JA, Benson NA, Chen MG, Braylan RC. Flow cytometric analysis of terminal deoxynucleotidyl transferase. Am J Clin Pathol 1991; 95: 376-380.
25. Gudelj L, Deniz G, Rukavina D, Johnson PM, Christmas SE. Expression of functional molecules by human CD3-decidual granular leucocyte clones. Immunology 1996; 87: 609-615.
26. Lichtenfels R, Biddison WE, Schultz H, Vogt AB, Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Meth 1994; 172: 227-239.
27. Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Bolentini A, Perletti L, Baldini L, Maiolo AT, Berti E. Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 1995; 86: 3160-3172.
28. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998; 15: 2469-2477.
29. Kobayashi S, Iwata T, Saito M, Iwasaki R, Matsumoto H, Naritaka S, Kono Y, Hayashi Y. Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan. Hum Genet 1996; 97: 424-430.
30. Prussin C, Foster B. TCR Vα24 and Vβ11 coexpression defines a human NKT cell analogue containing a unique Th0 subpopulation. J Immunol 1997; 159: 5862-5870.
31. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
33. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
34. Nakamura S, Suchi T, Koshikawa T, Kitoh K, Koike K, Komatsu H, lida S, Kagami Y, Ogura M, Katoh E, Kurita S, Suzuki H, Kobayashi Y, Yamabe H, Hirabayashi N, Ueda R, Takahashi T. Clinico-pathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995; 19: 284-296.
35. Yoneda N, Tatsumi E, Teshigawara K, Nagata S, Nakano T, Kishimoto Y, Kawano S, Kimura T, Yasunaga K, Yamaguchi N. Lineage determination of CD7+ CD5-CD2- and CD7+ CD5+ CD2-lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3ε, and CD3δ. Am J Hematol 1994; 45: 310-320.
36. Michalovitz D, Halevy O, Oren M: p53 mutations. Gains or losses? J Cell Biochem 1991; 45: 22-29.
37. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinnzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-830.
38. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79: 2378-2383.
39. Drexler HG, Fombonne S, Matsuo Y, Hu Z-B, Hamaguchi H, Uphoff CC. P53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 2000; 14: 198-206.
40. Karlhofer FM, Orihuela MM, Yokoyama WM. Ly-49-independent natural killer (NK) cell specificity revealed by NK cell clones derived from p53-deficient mice. J Exp Med 1995; 181: 1785-1795.
41. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658.
42. Ross E, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997; 89: 910-918.
43. Stanbrige FJ. Identifying tumor suppressor genes in human colorectal cancer. Science 1990; 247: 12-13.
44. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153-1156.
45. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995; 11: 763-770.
46. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
47. Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol 1999; 155: 955-965.
48. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, Uchiyama T, Maeda M. TCGF (IL-2)-receptor inducing factors: regulation of IL-2 receptors on a natural killer-like cell line (YT cells). J Immunol 1985; 134: 1623-1630.
49. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an agressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406-415.
50. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, Hiraki A, Nakayama H, Shibuya A, Ma Y, Kawabata T, Okada S, Harada M. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/ leukemia associated with Epstein-Barr virus infection. Blood 1998; 91: 1374-1383.
51. + phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998; 103: 669-677.
52. Drexler HG, Matsuo Y. Guidelines for the characterization and publication of human malignant hematopoietic cell lines. Leukemia 1999; 13: 835-842.